← Leaderboards
Christine M Sorenson
University Of Wisconsin-Madison
$3,477,825
Attributed
$3,477,825
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $816.4K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,477,825 · 4
By mechanism
R01$2,640,087 · 2
R21$837,738 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Ronald Danis$5,567,046
- Wei Xu$10,169,679
- Juliana M Falero-Perez$32,143
Others in their field
Top investigators on “Pathogenesis”
- Jeffrey P Krischer · University Of South Florida$473,867,135
- Constance Ann Benson · University Of California, San Diego$309,631,408
- Daniel R Kuritzkes · Brigham And Women'S Hospital$212,627,101
- Richard K. Wilson · Washington University$203,917,615
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$198,007,440
- Carol Nesel · Westat$147,274,423
Research focus
PathogenesisAffectFamily MemberPlayMediatingBlindnessModalityInnovationIn VitroBcl2 GeneExudative Age-Related Macular DegenerationNeovascularizationAge Related Macular DegenerationVisionChoroidal NeovascularizationApoptoticAllelesBlood VesselsCessation Of LifeLaser PhotocoagulationHomeostasisBruch&AposEndothelial CellsInflammation
Grant awards (11)
Bcl-2, Subretinal Scar Formation and Neovascular AMD$427,625
R21 · FY2023 · EY · contact PI
VEGF Antagonism and Resistance to Neovascular AMD$388,750
R01 · FY2023 · EY · contact PI
VEGF Antagonism and Resistance to Neovascular AMD$377,087
R01 · FY2022 · EY · contact PI
VEGF Antagonism and Resistance to Neovascular AMD$376,480
R01 · FY2021 · EY · contact PI
VEGF Antagonism and Resistance to Neovascular AMD$387,500
R01 · FY2020 · EY · contact PI
Bcl-2 and ocular neovascularization$184,363
R21 · FY2014 · EY · contact PI
Bcl-2 and ocular neovascularization$225,750
R21 · FY2013 · EY · contact PI
Bcl-2 & Branching Morphogenesis$267,698
R01 · FY2008 · DK · contact PI
Bcl-2 & Branching Morphogenesis$273,162
R01 · FY2007 · DK · contact PI
Bcl-2 & Branching Morphogenesis$281,320
R01 · FY2006 · DK · contact PI
Bcl-2 &Branching Morphogenesis$288,090
R01 · FY2005 · DK